Mechanistic enhancement of oral bioavailability through a coamorphous apremilast-aceclofenac systems: integrated LC-MS/MS Bioanalysis, in vivo pharmacokinetics, and PBPK modeling
European Journal of Pharmaceutics and Biopharmaceutics · 2026-08 · 225 · 115099
DOI: 10.1016/j.ejpb.2026.115099 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Pharmaceutics and Biopharmaceutics, 2026-08. Verfasst von Rahul Khemchandani und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, Telangana 500037, India; Analy…. Hauptthemen laut MEDLINE: Anti-Inflammatory Agents, Non-Steroidal, Diclofenac, Thalidomide. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 58 Literaturangaben.
Abstract (Originalsprache)
Poor aqueous solubility and dissolution-limited absorption remain major challenges in the oral delivery of apremilast (APR) and aceclofenac (ACF). In this study, coamorphous systems (CAMS) of APR-ACF were systematically evaluated to enhance biopharmaceutical and pharmacokinetic performance using an integrated experimental-computational approach. Three CAMS with different stoichiometric ratios (AA11, AA12, and AA21) were prepared and assessed. Solid-state analysis confirmed the formation of single-phase homogeneous CAMS stabilized by intermolecular interactions. CAMS showed significant improvements in solubility and dissolution compared to crystalline and physical mixtures, with AA12 exhibiting the greatest enhancement. A fully validated LC-MS/MS method was developed for simultaneous quantification of APR and ACF in rat plasma. In vivo pharmacokinetic studies revealed formulation-dependent increases in systemic exposure. AA12 enhanced APR's AUC (∼2.6-fold) and Cmax (∼1.5-fold) compared to crystalline drug, while ACF showed more moderate improvements (∼1.5-fold AUC, ∼1.3-fold Cmax). Tmax remained unchanged across formulations, indicating improved absorption extent. Physiologically based pharmacokinetic (PBPK) modeling incorporating the Advanced Compartmental Absorption and Transit (ACAT) framework, along with formulation-specific dissolution inputs, accurately predicted plasma concentration-time profiles and regional gastrointestinal absorption, confirming dissolution-driven absorption enhancement. This integrated in vitro-in vivo-in silico investigation establishes coamorphization as a validated strategy to overcome dissolution-limited absorption, identifying AA12 as the optimized CAMS for combined APR-ACF delivery.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, Telangana 500037, India; Analytical Research and Development, Novartis Healthcare Pvt Ltd, Hyderabad…
- Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research, Hyderabad, Telangana 500037, India.
- Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, Telangana 500037, India.
- Department of Biological Sciences, National Institute of Pharmaceutical Education and Research, Hyderabad, Telangana 500037, India.
- Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, Telangana 500037, India. Electronic address: gana.niperhyd@gov.in.
Zitieren
APA
Khemchandani, R., Pardhi, E., Jadhav, A., Shaikh, N., Bhale, N., Pilli, P., Pimpre, K., Chandra Mouli, H. M., Doijad, N., Mehra, N. K., Dikundwar, A. G., & Samanthula, G. (2026). Mechanistic enhancement of oral bioavailability through a coamorphous apremilast-aceclofenac systems: integrated LC-MS/MS Bioanalysis, in vivo pharmacokinetics, and PBPK modeling. European Journal of Pharmaceutics and Biopharmaceutics, 225, 115099. https://doi.org/10.1016/j.ejpb.2026.115099
Vancouver
Khemchandani R, Pardhi E, Jadhav A, Shaikh N, Bhale N, Pilli P, et al. Mechanistic enhancement of oral bioavailability through a coamorphous apremilast-aceclofenac systems: integrated LC-MS/MS Bioanalysis, in vivo pharmacokinetics, and PBPK modeling. European Journal of Pharmaceutics and Biopharmaceutics. 2026;225:115099. doi:10.1016/j.ejpb.2026.115099
BibTeX
@article{Khemchandani2026,
author = {Khemchandani, Rahul and Pardhi, Ekta and Jadhav, Aditya and Shaikh, Nadeem and Bhale, Nagesh and Pilli, Pushpa and Pimpre, Kavita and Chandra Mouli, H M and Doijad, Nandkumar and Mehra, Neelesh Kumar and Dikundwar, Amol G and Samanthula, Gananadhamu},
title = {Mechanistic enhancement of oral bioavailability through a coamorphous apremilast-aceclofenac systems: integrated LC-MS/MS Bioanalysis, in vivo pharmacokinetics, and PBPK modeling},
journal = {European Journal of Pharmaceutics and Biopharmaceutics},
year = {2026},
volume = {225},
pages = {115099},
doi = {10.1016/j.ejpb.2026.115099}
}
EUVIMED